Brief: Ligand Pharmaceuticals Q3 EPS USD -0.74
08/11/2023 21:01
Nov 08 (Reuters) - Ligand Pharmaceuticals Q3 basic EPS USD -0.74. * Q3 operating income USD -122 thousand * Q3 net income continuing operations USD -12.792 million * Q3 pretax profit USD -15.344 million * outlook FY revenue USD 126-129 million
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan